Cases | Controls | Optimal cut-off | Sensitivity % | Specificity % | PPV % | NPV % | p-value | |||
Subjects n | Mean (95% CI) | Subjects n | Mean (95% CI) | |||||||
Lymphocyte fraction % | 17 | 28.1 (18.9–37.4) | 73 | 15.7 (12.1–19.3) | 13 | 71 | 68 | 34 | 91 | <0.05 |
CD4+/CD8+ | 19 | 6.1 (5.2–7.0) | 83 | 3.7 (2.9–4.5) | 3.8 | 68 | 73 | 37 | 91 | <0.02 |
CD103+CD4+/CD4+ | 19 | 0.23 (0.20–0.27) | 82 | 0.32 (0.28–0.36) | 0.22 | 63 | 76 | 29 | 88 | 0.064 |
s-ACE U·L−1 | 17 | 119.0 (86.6–151.4) | 54 | 57.2 (49.2–62.2) | 84 | 82 | 89 | 70 | 94 | <0.001 |
PPV: positive predictive value; NPV: negative predictive value; s-ACE: serum angiotensin-converting enzyme.